Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
BACKGROUND
A prospective randomized study compared the preventive effects of ticlopidine plus aspirin therapy versus cilostazol plus aspirin therapy on subacute thrombosis (SAT) and restenosis after coronary stenting.


RESULTS
After successful stenting of 327 coronary lesions in 282 consecutive patients, the patients were randomized to receive ticlopidine (200 mg/day) or cilostazol (200 mg/day). Aspirin (81 mg/day) was administered concomitantly in both groups. SAT occurred in 1 patient in the ticlopidine group (0.7%) and in 8 patients in the cilostazol group (5.6%, p=0.037). Based on follow-up angiography, restenosis occurred in 30 patients (23.3%) in the ticlopidine group and 35 patients (26.9%) in the cilostazol group (NS). The late loss was significantly smaller in the cilostazol group than the ticlopidine group (1.08+/-0.95 mm vs 0.78+/-0.93 mm, respectively, p=0.037). No significant differences between the 2 groups were observed with respect to the rates of total death, non-fatal cardiovascular events, or bleeding complications.


CONCLUSIONS
The ticlopidine group showed significantly less SAT after stenting compared with the cilostazol group. After 6 months of treatment, the inhibition of neointimal proliferation was greater in the cilostazol group than in the ticlopidine group, but the prevention of restenosis was not confirmed.
Sekiguchi
Makoto
M
Division of Cardiology, Gunma Prefectural Cardiovascular Center, Gunma University, Maebashi, Japan. makoto-s@qj8.so-net.ne.jp
Hoshizaki
Hiroshi
H
Adachi
Hitoshi
H
Ohshima
Shigeru
S
Taniguchi
Koichi
K
Kurabayashi
Masahiko
M
D000368:Aged; D000077407:Cilostazol; D023903:Coronary Restenosis / Q000453:epidemiology*; D023921:Coronary Stenosis / Q000517:prevention & control / Q000601:surgery*; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents; D013777:Tetrazoles / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol; D013988:Ticlopidine